- Home
- HCKT vs RLMD Comparison
HCKT vs RLMD Comparison
Compare HCKT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | RLMD |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.0M | 319.7M |
| IPO Year | 1998 | 2012 |
Fundamental Metrics
Financial Performance| Metric | HCKT | RLMD |
|---|---|---|
| Price | $13.85 | $5.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $10.25 |
| AVG Volume (30 Days) | 343.8K | ★ 1.4M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $285,862,000.00 | $13,070.00 |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $30.67 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $12.76 | $0.24 |
| 52 Week High | $29.52 | $7.41 |
Technical Indicators
Market Signals| Indicator | HCKT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 59.58 |
| Support Level | $12.76 | $3.74 |
| Resistance Level | $21.13 | N/A |
| Average True Range (ATR) | 0.51 | 0.50 |
| MACD | 0.20 | 0.16 |
| Stochastic Oscillator | 44.39 | 52.70 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.